Cryptococcus Antigen Screen with Titer, Spinal Fluid
Use
Cryptococcosis is an invasive fungal infection caused by Cryptococcus neoformans or Cryptococcus gattii. The test aids in the diagnosis of cryptococcosis, particularly in patients with symptoms suggestive of central nervous system involvement, often in immunocompromised individuals. Presence of cryptococcal antigen in cerebrospinal fluid (CSF) indicates possible cryptococcosis. The test is crucial for diagnosing this infection, especially given its high mortality rate in untreated cases.
Special Instructions
This test should not be used as a general population screening procedure or for monitoring treatment response. If results are positive, a Cryptococcus titer test is added automatically. Test days are from Monday through Sunday, ensuring flexibility in sample processing and results.
Limitations
The test cannot be used as a test of cure nor to guide treatment decisions. It is not intended for general screening. A negative result does not exclude cryptococcosis diagnosis, especially if only one sample is tested. Traumatic lumbar puncture or specimen contamination can lead to false positives. Cross-reactivity with trichosporonosis has not been evaluated.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Lateral Flow)
Biomarkers
LOINC Codes
- 29896-8
- 29896-8
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
1 mL
Minimum Volume
0.5 mL
Container
Sterile vial
Collection Instructions
Submit specimen from collection vial 2 (preferred), 3, or 4.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 14 days |
| Frozen | 14 days |